Latest news with #ThermoFisherScientific
Yahoo
6 hours ago
- Business
- Yahoo
GE Vernova, Thermo Fisher, Enphase Energy: Trending Tickers
GE Vernova (GEV) stock is surging after beating second quarter estimates and raising its full-year outlook. Thermo Fisher Scientific (TMO) topped expectations and boosted its profit guidance. The company's CFO highlighted easing US–China tensions but warned sector-specific tariff woes could return. Enphase Energy (ENPH) stock is plummeting despite a second quarter earnings beat, as the company forecasts weaker third quarter sales and continues to struggle with subsidy cuts and trade tensions. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. Now time for some of today's Trending Tickers. We are watching GE Vernova, Thermo Fisher Scientific, and Enphase Energy. First up, shares of GE Vernova rising after the maker of gas turbines beat Wall Street expectations for the second quarter and also raised its full-year outlook. The company saw just over $9.1 billion in revenue in the second quarter. That was driven by a 44% increase in power orders while wind and electri electrification orders fell in the period. GE Vernova expects tariffs and inflation to represent a headwind of between $300 and $400 million. It also, though, raised its expectations for full-year revenue, adjusted EBITDA margins, and free cash flow. Next up, Thermo Fisher Scientific also beating expectations and raising its profit estimates for the year, saying it sees robust demand from its pharmaceutical client. Thermo Fisher makes pharmaceutical ingredients ingredients, as well as scientific instruments, among other things. Chief Financial Officer Stephen Williamson saying, quote, "The US-China tariff situation has improved significantly from April." That's despite promises from the Trump administration that pharma-sector specific tariffs are potentially coming later this year. Williamson, by the way, he's going to retire as CFO in March of next year to be replaced by vice president of financial operations, Jim Meyer. And finally, Enphase Energy shares sinking despite a second-quarter earnings beat as the maker of solar energy equipment anticipates a hit from the US-China trade war and the end of US electric subsidies. Enphase anticipates lower than anticipated third-quarter sales between $330 million and $370 million. Enphase shares have been battered in 2025. They've fallen by over 30% this year. Well, you can scan the QR code below to track the best and worst performing stocks with Yahoo Finance's Trending Tickers page. Related Videos Hilton's upbeat Q2 earnings: Why this analyst is still Neutral US equities lead 2025 ETF flows: A closer look at global trends Hasbro Q2 beat, MARA to raise $850M, Otis issues weak guidance Japanese auto stocks are surging on Trump's tariff deal Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
7 hours ago
- Business
- Yahoo
Thermo Fisher Scientific Stock Jumps on Strong Results, Higher Outlook
Thermo Fisher Scientific (TMO) shares took off after the maker of lab equipment and other life sciences products posted better-than-expected results and boosted its guidance, citing operational improvements and lower expected impacts from new tariffs. The company reported second-quarter adjusted earnings per share (EPS) of $5.36, with revenue rising 3% to $10.85 billion. Both exceeded estimates by analysts surveyed by Visible Alpha. Thermo Fisher attributed the performance to 'active management of our company in the macroenvironment,' pointing specifically to its growth strategy and Practical Process Improvement Business System (PPI). The "agility of our organization, powered by the PPI Business System, allowed us to effectively adapt to current market conditions, actively manage our cost base, and deliver strong operational results,' CEO Marc Casper said. Thermo Fisher updated its full-year adjusted EPS to a range of $22.22 to $22.84 from the previous outlook of $21.76 to $22.84. The tariff situation between the U.S. and China 'has improved significantly versus our prior guidance assumptions,' CFO Stephen Williamson said in a call with analysts, according to a transcript from AlphaSense. Also today, the company announced that Williamson will retire on March 31, 2026. Shares of Thermo Fisher Scientific are up about 12% in midday trading. Despite today's gains, they are down about 8% year-to-date. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
7 hours ago
- Business
- Globe and Mail
Thermo Fisher Q2 Earnings & Revenues Beat, Stock Up in Pre-Market
Thermo Fisher Scientific Inc. 's TMO second-quarter 2025 adjusted earnings per share (EPS) of $5.36 beat the Zacks Consensus Estimate by 2.7%. However, the figure decreased 0.2% year over year. The adjusted number excludes certain expenses, including asset amortization costs and certain restructuring costs. GAAP EPS was $4.28, up 6% on a year-over-year basis. Following the earnings announcement, shares of TMO rose 7.7% in pre-market trading today. TMO's Q2 Revenues in Detail Revenues in the quarter increased 2.9% year over year to $10.85 billion. Moreover, the top line surpassed the Zacks Consensus Estimate by 1.9%. Organic revenues in the reported quarter increased 2% year over year. Thermo Fisher's Segmental Analysis Thermo Fisher operates under four business segments, as discussed below: Life Sciences Solutions Revenues in the Life Sciences Solutions segment (23% of total revenues) increased 6.1% year over year to $2.50 billion. The number surpassed our model's estimate of $2.37 billion. Analytical Instruments Revenues in this segment (15.9%) declined 3% year over year to $1.73 billion. The figure missed our model's estimate of $1.84 billion. Specialty Diagnostics Revenues in the Specialty Diagnostics segment (10.4%) increased 1.5% year over year to $1.13 billion. The number missed our model's prediction of $1.15 billion. Laboratory Products and Biopharma Services Revenues in this segment (55.2%) rose 4.1% year over year to $5.99 billion. Our model's estimate was $5.71 billion. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) TMO's Margin Performance Gross margin of 41.2% in the second quarter contracted 83 basis points (bps) year over year due to a 4.4% increase in the cost of revenues. In the quarter, selling, general and administrative expenses rose 5.4% to $1.78 billion. Research and development expenses increased 3.8% to $352 million. The adjusted operating margin in the quarter was 21.6%, reflecting a contraction of 124 bps. Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise TMO's Financial Position The company ended the second quarter of 2025 with cash and cash equivalents and short-term investments of $6.39 billion compared with $5.95 billion at the end of the first quarter of 2025. Cumulative net cash from operating activities at the end of the second quarter was $2.12 billion compared with $3.21 billion a year ago. Thermo Fisher has a consistent dividend-paying history, with the five-year annualized dividend growth of 14.86%. Our Take on Thermo Fisher Stock Thermo Fisher exited the second quarter of 2025 with better-than-expected results, wherein both earnings and revenues beat the respective estimates. Barring the Analytical Instruments segment, all other business segments reported growth during the quarter. However, contraction of both margins in the quarter was discouraging. The company will provide its 2025 guidance on the earnings call today. During the second quarter, the company advanced in its growth strategy by launching a range of next-generation, high-impact, innovative instruments, including the Thermo Scientific Orbitrap Astral Zoom mass spectrometer, the Thermo Scientific Orbitrap™ Excedion Pro mass spectrometer and the Thermo Scientific Krios 5 Cryo-TEM. These instruments help researchers deepen the understanding of complex diseases, advance precision medicine and enable the development of new therapies. In addition, TMO expanded the DynaDrive single-use bioreactor portfolio for drug production to include a new first-of-its-kind bench-scale system, enabling meaningful workflow efficiencies and seamless scale-up from the bench to commercialization. All these developments translated into meaningful commercial wins for the company in the second quarter, which is encouraging. TMO's Zacks Rank & Key Picks Thermo Fisher currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Intuitive Surgical ISRG, Veeva Systems VEEV and Boston Scientific BSX. Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, posted first-quarter 2025 adjusted EPS of $1.81, which exceeded the Zacks Consensus Estimate by 5.9%. Revenues of $2.25 billion surpassed the Zacks Consensus Estimate by 3.3%. You can see the complete list of today's Zacks #1 Rank stocks here. ISRG has an estimated long-term earnings growth rate of 15.1% compared with the industry's 14.4%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.6%. Veeva Systems, currently carrying a Zacks Rank #2 (Buy), reported first-quarter fiscal 2026 adjusted EPS of $1.97, which surpassed the Zacks Consensus Estimate by 13.2%. Revenues of $759 million beat the consensus mark by 4.3%. VEEV has an estimated long-term earnings growth rate of 23.3% compared with the industry's 19.1%. The company beat on earnings in each of the trailing four quarters, the average surprise being 10%. Boston Scientific, carrying a Zacks Rank #2 at present, reported a first-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 0.1%. Revenues of $4.66 billion topped the Zacks Consensus Estimate by 20.9%. BSX has a long-term earnings growth rate of 13.2% compared with the industry's 13.9%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Boston Scientific Corporation (BSX): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Veeva Systems Inc. (VEEV): Free Stock Analysis Report
Yahoo
10 hours ago
- Business
- Yahoo
Thermo Fisher Scientific's Chief Financial Officer, Stephen Williamson, to Retire in Early 2026
Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 WALTHAM, Mass., July 23, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition, Williamson and Meyer will work closely together over the coming months. Williamson will remain an active member of the Company Leadership Team until his retirement in March 2026. "Stephen has played a key role in building the company into the industry leader we are today. He has overseen tremendous growth of the company with our market capitalization increasing nearly 300 percent during his tenure as CFO," said Marc N. Casper, chairman, president and chief executive officer. "I've worked closely with Stephen for nearly 25 years and have deeply valued his support, guidance and leadership. I wish him the very best in his upcoming retirement." Casper added, "As part of our long-planned succession process, we sought a leader with strong financial expertise and deep company knowledge, and Jim is exceptionally well qualified to take on this role. As a member of our Company Leadership Team, Jim has built strong relationships with leaders across the company. I've worked closely with Jim over the past few years and look forward to continuing our partnership as he steps into his new role." Meyer, age 46, joined Thermo Fisher in 2009 and held a number of finance leadership positions of increasing responsibility within the Laboratory Products, Analytical Instruments and Customer Channels businesses. In January 2023, he became vice president of financial operations, overseeing the finance support for all of the operating businesses within the company. Before joining Thermo Fisher, Jim worked for PricewaterhouseCoopers. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit View source version on Contacts Media Contact Information:Sandy PoundThermo Fisher ScientificPhone: 781-622-1223E-mail: Investor Contact Information:Rafael TejadaThermo Fisher ScientificPhone: 781-622-1356E-mail: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CTV News
11 hours ago
- Business
- CTV News
Thermo Fisher beats quarterly estimates on resilient demand for its tools and services
Sales at its laboratory products segment, which makes up more than half of Thermo Fisher's total sales came in at US$6 billion, above estimates of $5.79 billion.
